What is GamaMabs Pharma?
GamaMabs Pharma is a specialized French biotechnology enterprise at the forefront of immuno-oncology innovation. The company focuses on the development of optimized, first-in-class monoclonal antibodies that target AMHR2, a key protein involved in various cancer pathologies. By utilizing the proprietary EMABling technology, which enhances the tumor-killing efficacy of immune cells through low-fucose antibody engineering, GamaMabs Pharma addresses significant unmet needs in cancer treatment. The company's strategic focus on immune system activation positions it as a leader in the next generation of targeted cancer therapies, bridging the gap between fundamental research and clinical application.
How much funding has GamaMabs Pharma raised?
GamaMabs Pharma has raised a total of $22.3M across 2 funding rounds:
Series A
$5.7M
Series B
$16.6M
Series A (2014): $5.7M with participation from Alto Investments, iXO Private Equity, Bpifrance, and IRDI SORIDEC Gestion
Series B (2015): $16.6M led by Alto Invest, iXO Private Equity, Edmond de Rothschild Investment Partners, Bpifrance, and Irdinov
Key Investors in GamaMabs Pharma
Bpifrance
A French public investment bank that provides comprehensive financial support, including equity and credit, to companies across all stages of development to foster innovation and international growth.
iXO Private Equity
An independent French private equity firm specializing in small and mid-cap investments, with a strong commitment to supporting the growth of SMEs and ETIs through responsible investment practices.
Edmond de Rothschild Investment Partners
A prominent French investment banking firm that offers a diverse range of financial services and strategic solutions to support corporate growth and capital management.
What's next for GamaMabs Pharma?
With the support of its recent financing, GamaMabs Pharma is poised to scale its clinical operations and expand its therapeutic reach. The strategic roadmap involves deepening the validation of its lead candidates while exploring potential licensing opportunities and collaborative research ventures. As the company matures, the focus will likely shift toward optimizing its manufacturing processes and navigating the regulatory pathways required for international commercialization. The continued backing from its core investor base provides the necessary stability to pursue long-term value creation in the high-stakes oncology market, ensuring that its breakthrough antibody platforms remain at the cutting edge of medical science.
See full GamaMabs Pharma company page
